Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| RC2DK118619 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH |
Not provided
Not provided
Not provided
Not provided
The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
The study will ask participants to provide bile and/or bile duct cytology brushings at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal). The bile and brushings will be used to generate and perpetuate bile-derived organoids using an established matrigel-based protocol. These organoids will then be used in downstream experiments to better understand disease-specific alterations to biological pathways informative of disease pathogenesis
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Primary Sclerosing Cholangitis (PSC) | Subjects diagnosed with Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal). | ||
| Control (non-PSC) | Subjects without a diagnosis of Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal). |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants in study. | Number of participants in study. | 20 years |
| Measure | Description | Time Frame |
|---|---|---|
| Number of samples (per type) | Number of samples collected (bile liquid, biliary cells) | 20 years |
| Number of clinical phenotypes and/or observations. | Number of clinical phenotypes and/or endpoints observed (i.e. disease progression, liver ca development, organoids.) |
Not provided
Inclusion Criteria:
PSC
Controls
• Controls without history of PSC or evidence of other chronic liver disease of either gender that will participate in this study should be between the ages of 18-85.
Exclusion Criteria:
Not provided
Not provided
Subjects with Primary Sclerosing Cholangitis (PSC) and controls without PSC will be able to participate in this study.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Erik Schlicht, CCRP | Contact | (507) 284-4212 | schlicht.erik@mayo.edu | |
| Jackie Bianchi | Contact | (507) 266-0346 | bianchi.jackie@mayo.edu |
| Name | Affiliation | Role |
|---|---|---|
| Konstantinos Lazaridis, MD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic in Rochester | Recruiting | Rochester | Minnesota | 55905 | United States |
Not provided
| ID | Term |
|---|---|
| D015209 | Cholangitis, Sclerosing |
| D018281 | Cholangiocarcinoma |
| ID | Term |
|---|---|
| D002761 | Cholangitis |
| D001649 | Bile Duct Diseases |
| D001660 | Biliary Tract Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Collection of bile and biliary brushings collected at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).
| 20 years |
| D000230 |
| Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |